Ansamycin

	WikiDoc Resources for Ansamycin
Articles
Most recent articles on Ansamycin Most cited articles on Ansamycin Review articles on Ansamycin Articles on Ansamycin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ansamycin Images of Ansamycin Photos of Ansamycin Podcasts & MP3s on Ansamycin Videos on Ansamycin
Evidence Based Medicine
Cochrane Collaboration on Ansamycin Bandolier on Ansamycin TRIP on Ansamycin
Clinical Trials
Ongoing Trials on Ansamycin at Clinical Trials.gov Trial results on Ansamycin Clinical Trials on Ansamycin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ansamycin NICE Guidance on Ansamycin NHS PRODIGY Guidance FDA on Ansamycin CDC on Ansamycin
Books
Books on Ansamycin
News
Ansamycin in the news Be alerted to news on Ansamycin News trends on Ansamycin
Commentary
Blogs on Ansamycin
Definitions
Definitions of Ansamycin
Patient Resources / Community
Patient resources on Ansamycin Discussion groups on Ansamycin Patient Handouts on Ansamycin Directions to Hospitals Treating Ansamycin Risk calculators and risk factors for Ansamycin
Healthcare Provider Resources
Symptoms of Ansamycin Causes & Risk Factors for Ansamycin Diagnostic studies for Ansamycin Treatment of Ansamycin
Continuing Medical Education (CME)
CME Programs on Ansamycin
International
Ansamycin en Espanol Ansamycin en Francais
Business
Ansamycin in the Marketplace Patents on Ansamycin
Experimental / Informatics
List of terms related to Ansamycin

Ansamycins is a family of secondary metabolites that show antimicrobial activity against many gram-positive and some gram-negative bacteria and includes various compounds among which: streptovaricins and rifamycins ^[1]. In addition, these compounds demonstrated antiviral activity towards bacteriophages and poxviruses. They are named ansamycins—ansa from the Latin for handle—because of their unique structure which comprises an aromatic moiety bridged by an aliphatic chain ^[2]. The main difference between various derivatives of ansamycins is the aromatic moiety, which can be a naphthalene ring or a naphthoquinone ring as in rifamycin and naphthomycin ^[3]. Another variation comprises benzene or a benzoquinone ring system as in geldanamycin or ansamitocin. Ansamycins were first discovered in 1959 by Sensi et al from Amycolatopsis mediterranei, an Actinomycete.^[4] Rifamycins are a subclass of ansamycins with high potency against mycobacterial activity. This resulted in their wide use in the treatment of tuberculosis, leprosy, and AIDS-related mycobacterial infections.^[5] Since then various analogues have been isolated from other prokaryotes.

References

↑ Wehrli, W.; Staehelin, M. (1971). "Actions of the rifamycins". Bacteriol. Rev. 35: 290.
↑ Prelog, V.; Oppolzer, W. (1973). "Rifamycins. 4. Ansamycins, a novel class of microbial metabolism products". Helv. Chim. Acta. 56: 2279.
↑ Balerna, M.; Keller-Schierlein, W.; Martius, C.; Wolf, H.; Zähner, H. (1969). "Metabolic products of microorganisms. 72. Naphthomycin, an antimetabolite of vitamin K". Arch. Mikrobiol. 65: 303.
↑ Sensi, P.; Margalith, P.; Timbal, M. T. (1959). "Rifomycin, a new antibiotic; preliminary report". Ed. Sci. 14: 146.
↑ Floss, H. G.; Yu, T. (1999). "Lessons from the rifamycin biosynthetic gene cluster". Curr. Opin. Chem. Biol. 3: 592.

Template:WS

[1] Wehrli, W.; Staehelin, M. (1971). "Actions of the rifamycins". Bacteriol. Rev. 35: 290.

[2] Prelog, V.; Oppolzer, W. (1973). "Rifamycins. 4. Ansamycins, a novel class of microbial metabolism products". Helv. Chim. Acta. 56: 2279.

[3] Balerna, M.; Keller-Schierlein, W.; Martius, C.; Wolf, H.; Zähner, H. (1969). "Metabolic products of microorganisms. 72. Naphthomycin, an antimetabolite of vitamin K". Arch. Mikrobiol. 65: 303.

[4] Sensi, P.; Margalith, P.; Timbal, M. T. (1959). "Rifomycin, a new antibiotic; preliminary report". Ed. Sci. 14: 146.

[5] Floss, H. G.; Yu, T. (1999). "Lessons from the rifamycin biosynthetic gene cluster". Curr. Opin. Chem. Biol. 3: 592.

[1]

[2]

[3]

[4]

[5]

Ansamycin

References

Navigation menu